Continued strong Cresemba® (isavuconazole) sales trigger second sales milestone this year from Pfizer to Basilea of USD 7 million
(WorldNews Switzerland)

Basel, Switzerland, December 06, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that sales of the antifungal Cresemba® (isavuconazole) by Pfizer in Europe and Israel exceeded the threshold triggering a sales milestone payment to Basilea of USD 7 million. Basilea is entitled to receive sales milestone payments upon Pfizer`s cumulative Cresemba sales in Pfizer`s licensed territories exceeding certain thresholds. The first sales milestone was triggered early in 2019 and amounted to USD 5 million. Pfizer is currently commercializing Cresemba in many European countries, including France, Germany, Italy, Spain and the U.K, as well as in Israel and in Singapore, the first launched...